Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: CYMBALTA

« Back to Dashboard
Cymbalta is a drug marketed by Lilly and is included in one NDA. It is available from eighteen suppliers. There are two patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in CYMBALTA is duloxetine hydrochloride. There are thirty-six drug master file entries for this compound. Eighteen suppliers are listed for this compound. There are three tentative approvals for this compound. Additional details are available on the duloxetine hydrochloride profile page.

Summary for Tradename: CYMBALTA

Suppliers / Packagers: see list66
2013 Sales:$5,219,860,000

Clinical Trials for: CYMBALTA

The Cymbalta Pregnancy Registry
Status: Recruiting Condition: Pregnancy

Study of Duloxetine in the Reduction of Pain in Patient With Systemic Lupus Erythematosus
Status: Completed Condition: Systemic Lupus Erythematosus

Feasibility Study of Duloxetine in the Treatment of Depression in Patients With Traumatic Brain Injury
Status: Terminated Condition: Traumatic Brain Injury; Depression

Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome
Status: Completed Condition: Anxiety Disorder

A Study for the Treatment of Diabetic Peripheral Neuropathic Pain
Status: Completed Condition: Diabetic Neuropathies

An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain
Status: Completed Condition: Diabetic Neuropathy, Painful

Bioavailability Study of Duloxetine Delayed-Relase Capsules 60 mg Under Fed Condition
Status: Completed Condition: Healthy

Bioavailability Study of Duloxetine Delayed-Release Capsules 60 mg Under Fasting Condition
Status: Completed Condition: Healthy

A Study to Evaluate the Pharmacokinetics of Duloxetine in Chinese Han Healthy Subjects
Status: Completed Condition: Healthy

Cymbalta for Fibromyalgia Pain
Status: Recruiting Condition: Fibromyalgia

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
duloxetine hydrochloride
CAPSULE, DELAYED REL PELLETS;ORAL021427-001Aug 3, 2004RXNo6,596,756*PED<disabled>Y<disabled>
duloxetine hydrochloride
CAPSULE, DELAYED REL PELLETS;ORAL021427-004Aug 3, 2004RXYes<disabled><disabled>
duloxetine hydrochloride
CAPSULE, DELAYED REL PELLETS;ORAL021427-002Aug 3, 2004RXNo6,596,756*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: CYMBALTA

Drugname Dosage Strength RLD Submissiondate
duloxetine hydrochlorideDelayed-release Capsules40 mgCymbalta5/10/2012
duloxetine hydrochlorideDelayed-release Capsules20 mg, 30 mg and 60 mgCymbalta8/4/2008
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn